[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS65052B1 - Farmaceutska formulacija - Google Patents

Farmaceutska formulacija

Info

Publication number
RS65052B1
RS65052B1 RS20240029A RSP20240029A RS65052B1 RS 65052 B1 RS65052 B1 RS 65052B1 RS 20240029 A RS20240029 A RS 20240029A RS P20240029 A RSP20240029 A RS P20240029A RS 65052 B1 RS65052 B1 RS 65052B1
Authority
RS
Serbia
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
RS20240029A
Other languages
English (en)
Inventor
Simon Geissler
Martina Jeschke
Patrizia Boniforte
Markus Weigandt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of RS65052B1 publication Critical patent/RS65052B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20240029A 2017-03-30 2018-03-28 Farmaceutska formulacija RS65052B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17163830 2017-03-30
EP18715593.2A EP3601277B1 (en) 2017-03-30 2018-03-28 Pharmaceutical formulation
PCT/EP2018/057877 WO2018178134A1 (en) 2017-03-30 2018-03-28 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
RS65052B1 true RS65052B1 (sr) 2024-02-29

Family

ID=58461174

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240029A RS65052B1 (sr) 2017-03-30 2018-03-28 Farmaceutska formulacija

Country Status (22)

Country Link
US (2) US11559490B2 (sr)
EP (2) EP3601277B1 (sr)
JP (1) JP7228524B2 (sr)
KR (1) KR102708265B1 (sr)
CN (1) CN110446707B (sr)
AU (1) AU2018246258B2 (sr)
CA (1) CA3058286A1 (sr)
DK (1) DK3601277T3 (sr)
ES (1) ES2968399T3 (sr)
FI (1) FI3601277T3 (sr)
HR (1) HRP20231748T1 (sr)
HU (1) HUE064474T2 (sr)
IL (2) IL301979B2 (sr)
LT (1) LT3601277T (sr)
MX (1) MX2019011639A (sr)
PL (1) PL3601277T3 (sr)
PT (1) PT3601277T (sr)
RS (1) RS65052B1 (sr)
SG (1) SG11201909062WA (sr)
SI (1) SI3601277T1 (sr)
TW (2) TW202402297A (sr)
WO (1) WO2018178134A1 (sr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN114072396B (zh) * 2019-06-27 2024-02-02 南京明德新药研发有限公司 作为dna-pk抑制剂的喹啉和噌啉衍生物
WO2022058323A1 (en) 2020-09-18 2022-03-24 Merck Patent Gmbh Compounds for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2712010A1 (en) * 2008-01-11 2009-07-12 Cipla Limited Solid pharmaceutical dosage form
EP2105130A1 (de) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
IN2011CH01887A (sr) 2011-06-02 2012-12-14
CA2852058C (en) * 2011-10-14 2021-06-01 Array Biopharma Inc. A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
US20160000720A1 (en) * 2013-02-14 2016-01-07 Aurobindo Pharma Limited Pharmaceutical compositions comprising Tadalafil
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
RU2696578C1 (ru) 2014-02-05 2019-08-05 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法

Also Published As

Publication number Publication date
EP3601277B1 (en) 2023-10-11
IL269668B1 (en) 2023-05-01
RU2019133789A3 (sr) 2021-07-12
LT3601277T (lt) 2024-01-25
IL269668A (en) 2019-11-28
AU2018246258B2 (en) 2021-07-29
TWI808077B (zh) 2023-07-11
CN110446707A (zh) 2019-11-12
CA3058286A1 (en) 2018-10-04
SI3601277T1 (sl) 2024-02-29
IL269668B2 (en) 2023-09-01
IL301979B2 (en) 2024-05-01
EP4286007A2 (en) 2023-12-06
PT3601277T (pt) 2024-01-11
EP3601277A1 (en) 2020-02-05
EP4286007A3 (en) 2024-04-10
RU2019133789A (ru) 2021-04-30
JP7228524B2 (ja) 2023-02-24
PL3601277T3 (pl) 2024-07-08
WO2018178134A1 (en) 2018-10-04
HUE064474T2 (hu) 2024-03-28
US20210085611A1 (en) 2021-03-25
TW201902485A (zh) 2019-01-16
JP2020512367A (ja) 2020-04-23
US11559490B2 (en) 2023-01-24
HRP20231748T1 (hr) 2024-03-15
KR20190130017A (ko) 2019-11-20
DK3601277T3 (da) 2024-01-15
KR102708265B1 (ko) 2024-09-20
BR112019020269A2 (pt) 2020-04-22
IL301979A (en) 2023-06-01
FI3601277T3 (fi) 2024-01-09
IL301979B1 (en) 2024-01-01
CN110446707B (zh) 2024-03-08
ES2968399T3 (es) 2024-05-09
SG11201909062WA (en) 2019-10-30
MX2019011639A (es) 2019-12-05
AU2018246258A1 (en) 2019-11-14
TW202402297A (zh) 2024-01-16
US20230119567A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
GB201807942D0 (en) Pharmaceutical formulation
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271226A (en) medical preparation
ZA201903101B (en) Pharmaceutical formulations
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL271759A (en) Pharmaceutical preparations that include anthraxtinib
ZA202102871B (en) Pharmaceutical formulation
HK1245653A1 (zh) 藥物製劑
IL278927A (en) pharmaceutical preparation
IL266537A (en) pharmaceutical preparation
IL253177A0 (en) Pharmacy preparation
IL269239A (en) A pharmaceutical combination containing fonsimod
EP3383371C0 (en) PHARMACEUTICAL FORMULATION
ZA201807851B (en) Pharmaceutical formulation
PT3601277T (pt) Formulação farmacêutica
GB201506755D0 (en) Novel pharmaceutical formulation
IL275144A (en) Pharmacy preparation
GB201511246D0 (en) Pharmaceutical formulation
IL271908A (en) Over-compressed pharmaceutical preparations
GB201719873D0 (en) Pharmaceutical formulation
GB201604545D0 (en) Novel pharmaceutical formulation
GB201610440D0 (en) Pharmaceutical formulations